丙型肝炎直接抗病毒药物的临床研究进展

Recent Advances in Direct-acting Antivirals for the Treatment of Hepatitis C

全口服的直接抗病毒药物(DAA)的上市是丙型肝炎治疗史上的重要里程碑。在中国目前已经或即将获批上市的DAA包括达拉他韦、阿舒瑞韦、索磷布韦、奥比帕利、达塞布韦和西美瑞韦,这些药物组合的治愈率高、安全性好,将使更多中国丙肝患者获得治愈。对上述丙型肝炎DAA方案的临床研究情况深入回顾,并对丙型肝炎治疗的发展目标及泛基因型丙肝鸡尾酒疗法的突出代表进行简介,以期为丙型肝炎及相关药物的研发提供参考。

The development of all-oral direct-acting antiviral agents（DAA） is a milestone in the history of hepatitis C treatment. In China, DDAs that have been approved or will be approved in the near future include daclatasvir, asunaprevir, sofosbuvir, ombitasvir/paritaprevir/ritonavir, dasabuvir and simeprevir. With high efficacy and good safety, these drug combinations make it possible to cure more Chinese patients with hepatitis C. The clinical trial data of the above-mentioned medicines were reviewed here, and the development goal of hepatitis C treatment and the prominent representatives of pan-genotypic combination of direct-acting antiviral agents were introduced, so as to provide reference for researches of hepatitis C and related drugs.